A Phase III, Randomised, Double-blind and Open Label Phase, Active and Placebo Controlled Study Comparing the Short-term Efficacy of Two Formulations of Clostridium Botulinum Type A Toxin (Dysport and Dysport NG) to Placebo, and Assessing the Short and Long Term Efficacy and Safety of Dysport NG Following Repeated Treatments of Subjects With Cervical Dystonia
Latest Information Update: 29 Oct 2021
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Torticollis
- Focus Registrational; Therapeutic Use
- Sponsors Ipsen
- 22 Sep 2021 Results assessing meta-analysis of patient-level data from four randomized, placebo-controlled studies (Truong et al 2005 & 2010, NCT01261611, NCT01753310) of AboBoNT-A 500U and three associated open-label extension studies were presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.
- 22 Apr 2021 Results of meta analyses of patient level data from four randomized, placebo controlled studies (Truong et al 2005 & 2010, NCT01261611, NCT01753310) of AboBoNT-A 500U and three associated open-label extension studies presented at the 73rd Annual Meeting of the American Academy of Neurology
- 14 Nov 2014 Results were presented at the Annual Assembly of the Academy of Physical Medicine and Rehabilitation (AAPM&R) according to an Ipsen media release reporting the results.